Observational studyInternal and emergency medicine2026
Impact of comorbidities and organ damage on hospital admissions and mortality in patients with sarcoidosis: an observational study from the Spanish National Registry.
Observational study in Internal and emergency medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Outdated Frameworks, Missed Opportunities: A Call for Establishing Classification Criteria for Patients with Sarcoidosis.Rheumatology and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advanced lung disease, cardiovascular disease (CVD), infections, malignancies, and thromboembolic disease (TED) determine the mortality of patients with sarcoidosis. Our objective was to evaluate the main causes of admission and in-hospital mortality in patients with sarcoidosis in Spain. A retrospective and observational analysis of the National Registry of Hospital Discharges (RAE-CMBD) of patients admitted with a diagnosis of sarcoidosis between 2016 and 2021 was performed. A total of 18,887 admissions of patients with sarcoidosis were identified. The main causes of admission were infection (21%), sarcoidosis itself (16.4%), CVD (12.7%), and malignancies (7.1%). Overall, 892 (4.7%) patients died, mainly from infection (32.1%), CVD (16.3%) and neoplasms (12.4%), with case fatality rates of 7.2%, 6% and 8.3%, respectively. Factors associated with higher in-hospital mortality were Charlson comorbidity index (OR 1.30 95%CI 1.27-1.34), sarcoidosis pulmonary involvement (OR = 1.20, 95%CI 1.04-1.38), pulmonary fibrosis (OR 2.07; 95%CI 1.52-2.81) and CVD (OR 1.56; 95%CI 1.26-1.95), infection (OR 2.37; 95%CI 1.97-2.84), malignancies (OR 1.77; 95%CI 1.38-2.27) and TE-related admissions (OR 2.1, 95%CI 1.21-3.76). The main determinants of hospital admissions and mortality in patients with sarcoidosis are infections, CVD, neoplasm, VTE, pulmonary fibrosis, and a high comorbidity burden. While sarcoidosis itself is a common cause of admission, it is rarely the cause of death. Prevention of infections, VTE, and neoplasm, along with control of cardiovascular risk factors, may help reduce mortality in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.